Novo Nordisk is a global pharmaceutical company specializing in diabetes, obesity, and selected rare diseases. Its portfolio includes insulin therapies and GLP-1-based medicines such as Ozempic and Wegovy, supported by significant investment in drug delivery and manufacturing capacity. The business develops, produces, and markets chronic-disease treatments, with demand tied closely to metabolic-health therapies.
Novo Nordisk ADR (NVO) has a MarketKingdoms composite score of 62.9 (B-), an B-range rating. It ranks 1036th of 1,866 covered companies, 49th of 78 in Healthcare (sector average 64.4) and 8th of 13 in Drug Manufacturers - General. Scores as of 2026-10-26.
Its strongest lenses are Catalyst watch at 86 (Healthcare average 74) and Industry opportunity at 81 (Healthcare average 81). Its weakest lenses are Trend (momentum) at 10 (sector average 50) and Expansion (growth) at 22 (sector average 50).
| Lens | Type | NVO | Healthcare average | Drug Manufacturers - General average | Percentile in sector |
|---|---|---|---|---|---|
| Industry opportunity | Research signal | 81 | 81 | 81 | 65th |
| Stock selection | Research signal | 76 | 79 | 78 | 31st |
| KPI momentum | Research signal | 58 | 78 | 77 | 9th |
| Catalyst watch | Research signal | 86 | 74 | 71 | 100th |
| Price (valuation) | Fundamental lens | 69 | 50 | 53 | 78th |
| Expansion (growth) | Fundamental lens | 22 | 50 | 39 | 8th |
| Quality (profitability) | Fundamental lens | 77 | 50 | 60 | 90th |
| Trend (momentum) | Fundamental lens | 10 | 50 | 55 | 9th |
The most recent call analysed was held on 2026-08-05 (fiscal 2026 Q2). After it the composite moved from 79.7 to 79.0. MarketKingdoms checks what management promised on each call against what it later delivered.
The composite at the time of each event; today's composite is 62.9.
The stock's valuation gap is -24.0%: its price is well below the path its market, sector and industry moves explain (strongly undervalued versus the model path). Factor sensitivity: market beta 0.33, sector beta 0.78, industry beta 0.30; the factor model explains 25% of its moves (R²).
| Company | Composite | Grade | Valuation gap |
|---|---|---|---|
| Amgen Inc. (AMGN) | 71.9 | B+ | +13.9% |
| Eli Lilly & Co. (LLY) | 71.2 | B+ | +1.7% |
| AbbVie Inc. (ABBV) | 69.0 | B | -3.2% |
| Bristol-Myers Squibb Co. (BMY) | 66.3 | B | -11.0% |
| Biogen Inc. (BIIB) | 65.9 | B | +31.0% |
| Gilead Sciences Inc. (GILD) | 65.5 | B | -3.5% |
| GSK plc ADR (GSK) | 63.0 | B- | -5.1% |
| Novartis AG ADR (NVS) | 62.1 | B- | -3.9% |
Novo Nordisk ADR financial statements · Healthcare sector ranking · Drug Manufacturers - General industry ranking · All covered companies
The composite score (0–100, graded A+ to D-) blends research signals from each earnings call with fundamental lenses from SEC filings and market prices. Research signals: Industry opportunity, Stock selection, KPI momentum and Catalyst watch, read from what management said and whether it delivered. Fundamental lenses: Price (valuation), Expansion (growth), Quality (profitability) and Trend (momentum). Scores are recalculated every night and after every earnings call. The valuation gap compares the actual price path with the path the stock's market, sector and industry moves explain; it is a model comparison, not a fair-value estimate.
General information, not investment advice.